Philip Dean

• 
  www.prelude-trust.co.uk/news/portfoliorelease.jsp?actua - [Cached Version]
  Published on: 5/9/2006    Last Visited: 8/18/2008  

  Philip Dean, Chief Scientific Officer at De Novo, commented: "Metabolic diseases is an important therapeutic area with many targets that present a major opportunity for De Novo[s technologies.

• 
  BIO.COM: Biotechnology Pharmaceutical Market, Stocks,... - [Cached Version]
  Published on: 1/17/2006    Last Visited: 1/20/2006  

  "We are very pleased to be working with Genzyme," said Philip Dean, Ph.D., CSO at De Novo."Using SkelGen, we will be designing for Genzyme new chemical classes of inhibitors to an important biological target implicated in multiple diseases", he added.
  ...
  With regard to the De Novo Technology, Philip added "The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ.

• 
  Bio - Philip Dean - [Cached Version]
  Published on: 5/3/2006    Last Visited: 7/10/2007  

  Philip Dean
  ...
  Philip Dean moved to the University of Cambridge in 1967 to work for a PhD on biophysical correlations in cell secretions at the Department of Pharmacology.He has spent 33 years of his working life within the university, much of it with funding from the Wellcome Trust.The last ten years at the university were linked to research contracts with Rhone-Poulenc (Rhone-Poulenc Rorer) (Aventis) where his team was responsible for the development of novel algorithms in biomolecular structural problems, principally molecular similarity in drug design.
  
  The research at Cambridge University culminated with a large grant from Rhone-Poulenc to develop novel technologies for drug design to handle the expected avalanche of genomic material.In 2000 Philip's research team was spun out of the University into De Novo Pharmaceuticals where today he is co-founder and Chief Scientific Officer.

• 
  Business Briefings - Directory Listing - [Cached Version]
  Published on: 6/1/2003    Last Visited: 2/21/2004  

  Dr Philip Dean Co-founder and Chief Scientific Officer, De Novo Pharmaceuticals

• 
  CHI's Structure-Based Drug Design - [Cached Version]
  Published on: 8/31/1999    Last Visited: 5/25/2006  

  Dr. Philip M. Dean, De Novo Pharmaceuticals Ltd.
  ...
  Dr. Philip M. Dean, Chief Scientific Officer, De Novo Pharmaceuticals Ltd.The pharmacophore hypothesis has been of great value for drug design and development.

• 
  Christian Monitor - Help planned for street kids in... - [Cached Version]
  Published on: 11/19/2007    Last Visited: 9/1/2008  

  Speaking at the ceremony the Co-founder of the organisation, Philip Dean stated, ,the

• 
  Combinatorial Chemistry - De Novo Announces Drug... - [Cached Version]
  Published on: 1/19/2006    Last Visited: 2/5/2006  

  "We are very pleased to be working with Genzyme," said Philip Dean, Ph.D., CSO at De Novo.
  
  "Using SkelGen, we will be designing for Genzyme new chemical classes of inhibitors to an important biological target implicated in multiple diseases," he added.
  ...
  With regard to the De Novo Technology, Philip added, "The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ."

• 
  DE NOVO PHARMACEUTICALS ANNOUNCES DRUG DISCOVERY... - [Cached Version]
  Published on: 1/1/2006    Last Visited: 7/11/2006  

  "We are very pleased to be working with Genzyme," said Philip Dean, Ph.D., CSO at De Novo."Using SkelGen, we will be designing for Genzyme new chemical classes of inhibitors to an important biological target implicated in multiple diseases", he added.
  ...
  With regard to the De Novo Technology, Philip added "The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ.

• 
  De Novo Announces New Partnering Opportunity in... - [Cached Version]
  Published on: 4/9/2007    Last Visited: 6/11/2008  

  Philip Dean, Chief Scientific Officer at De Novo, commented: "Metabolic disease is an important therapeutic area with many targets that present a major opportunity for De Novo`s technologies.

• 
  De Novo Pharmaceuticals Enters Drug Discovery... - [Cached Version]
  Published on: 1/18/2006    Last Visited: 1/18/2006  

  "We are very pleased to be working with Genzyme," said Philip Dean, Ph.D., CSO at De Novo."Using SkelGen, we will be designing for Genzyme new chemical classes of inhibitors to an important biological target implicated in multiple diseases," he added.
  ...
  With regard to the De Novo Technology, Philip added "The core algorithm generates new molecular structures by the random assembly of small molecular fragments in situ.

Page:  1 2 3